BVF Stoklara Genel Bakış Bausch Health Companies Inc. Amerika Birleşik Devletleri'nde ve uluslararası alanda çeşitlendirilmiş bir özel ilaç ve tıbbi cihaz şirketi olarak faaliyet göstermektedir. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Bausch Health Companies Inc. Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Bausch Health Companies Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı US$7.93 52 Haftanın En Yüksek Seviyesi US$9.82 52 Haftanın En Düşük Seviyesi US$4.69 Beta 0.69 1 Aylık Değişim -8.40% 3 Aylık Değişim 4.34% 1 Yıllık Değişim 10.29% 3 Yıllık Değişim -67.33% 5 Yıllık Değişim -68.62% Halka arzdan bu yana değişim -12.26%
Son Haberler & Güncellemeler
Bausch Health Companies Inc. Appoints Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D Dec 02
Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada Nov 19
Third quarter 2024 earnings released: US$0.23 loss per share (vs US$1.03 loss in 3Q 2023) Nov 01
Forecast breakeven date moved forward to 2024 Nov 01
Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA Oct 28
Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 10 Daha fazla güncelleme görün
Bausch Health Companies Inc. Appoints Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D Dec 02
Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada Nov 19
Third quarter 2024 earnings released: US$0.23 loss per share (vs US$1.03 loss in 3Q 2023) Nov 01
Forecast breakeven date moved forward to 2024 Nov 01
Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA Oct 28
Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 10
Health Canada Approves the Bausch Health's (Pr)CABTREO Topical Gel Sep 11
Second quarter 2024 earnings released: EPS: US$0.027 (vs US$0.071 in 2Q 2023) Aug 02
Bausch Health Companies Inc. Raises Earnings Guidance for the Full Year 2024 Aug 01 Bausch Health Companies Inc. Announces Appointment of Aimee Lenar as Executive Vice President, US Pharma
Bausch Health Companies Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 12
Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024 May 18
Bausch Health Companies Inc. Approves Directorate Appointments May 16
First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.55 loss in 1Q 2023) May 03
Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan Apr 13
Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024 Apr 12
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults Apr 03
Insufficient new directors Apr 01
Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma Mar 06
Full year 2023 earnings released: US$1.62 loss per share (vs US$0.62 loss in FY 2022) Feb 23
Bausch Health Companies Inc., Annual General Meeting, May 14, 2024 Feb 21 Bausch Health Companies Inc. to Report Q4, 2023 Results on Feb 22, 2024
Bausch Health Companies Inc. Announces the U.S. Launch of CABTREO Topical Gel Jan 31
Bausch Health Companies Inc. and Salix Pharmaceuticals Ltd. Provides Update on Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute Jan 09
Bausch Health Companies Inc. Announces Positive Topline Results from Global Phase 2 Study Evaluating Amiselimod (An S1p Antagonist) to Treat Ulcerative Colitis Dec 22
No longer forecast to breakeven Dec 21
Bausch Health, Canada Announces DUOBRII Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug Plan Dec 19
No longer forecast to breakeven Nov 07
Third quarter 2023 earnings released: US$1.04 loss per share (vs US$1.10 profit in 3Q 2022) Nov 03
FDA Approves Bausch Health Companies Inc. and Its Dermatology Business, Ortho Dermatologics's Cabtreo Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older Oct 21
Bausch Health Companies Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 13 Bausch Health Companies Inc. Announces Executive Changes
Bausch Health Companies Inc. Announces New Treatment PrUCERIS (Budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults Sep 14
Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc Sep 08
Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc Sep 06
Bausch Health Companies Inc. Raises Earnings Guidance for the Fiscal Year 2023 Aug 04
Second quarter 2023 earnings released: EPS: US$0.072 (vs US$0.40 loss in 2Q 2022) Aug 04
Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of Bausch Health Companies Inc Jul 27
Bausch Health Companies Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 14
New major risk - Financial position Jul 03
No longer forecast to breakeven May 22
Forecast to breakeven in 2025 May 09
First quarter 2023 earnings released: US$0.56 loss per share (vs US$0.19 loss in 1Q 2022) May 05
Bausch Health Companies Inc. Provides Consolidated Earnings Guidance for the Full Year 2023 May 05
Forecast breakeven date pushed back to 2025 Apr 18
Full year 2022 earnings released: US$0.62 loss per share (vs US$2.64 loss in FY 2021) Feb 24
Investor sentiment improves as stock rises 23% Feb 22
Bausch Health Companies Inc. to Report Q4, 2022 Results on Feb 23, 2023 Feb 02
Investor sentiment improved over the past week Jan 07
Bausch Health Companies Inc. Announces Availability of ARAZLOTM Dec 23
Third quarter 2022 earnings released: EPS: US$1.10 (vs US$0.52 in 3Q 2021) Nov 04
Bausch Health Companies Inc. Revises Consolidated Earnings Guidance for the Full Year 2022 Nov 04
Bausch Health Companies Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 14
Bausch Health Companies Inc. and Glenmark Specialty S.A. Announce the Approval of RYALTRIS® in Canada Sep 23
Insider recently sold €708k worth of stock Sep 21 Bausch Health Companies Inc.(TSX:BHC) dropped from FTSE All-World Index (USD)
Investor sentiment improved over the past week Sep 13
Bausch Health Companies Inc. Responds to Norwich Pharmaceuticals Tentative FDA Approval for 200 mg Rifaximin Sep 10
Investor sentiment improved over the past week Aug 16 Bausch Health Companies Inc. to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit
Second quarter 2022 earnings released Aug 10 Bausch Health Companies Inc. Announces Unaudited Impairment Results for the Quarter Ended June 30, 2022
Insufficient new directors Jul 31
Bausch Health Companies Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jul 28
Insufficient new directors Jul 01
Bausch Health Companies Inc. Announces Updates to Its Board of Directors Jun 24
Bausch Health Companies Inc. Appoints John S. Barresi as the Company’s Senior Vice President, Controller and Chief Accounting Officer Jun 01
Bausch Health Companies Inc. Provides Revenue Guidance for the Year Full Year 2022 May 12
Bausch Health Companies Inc. Announces Management Changes May 08
Bausch Health Companies Inc. to Report Q1, 2022 Results on May 10, 2022 May 02
Bausch Health Companies Inc., Annual General Meeting, Jun 14, 2022 Apr 02
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 26 Bausch Health Companies Inc. Provides Earnings Guidance for the Year 2022
Bausch Health, Canada Announces Availability through Pharmacies Across Canada of its New Prescription Treatment TRULANCE Feb 09
Bausch Health Companies Inc. to Report Q4, 2021 Results on Feb 23, 2022 Feb 04
Insufficient new directors Jan 21
Bausch Health Companies Inc. has filed an IPO. Jan 15
Bausch Health Companies Inc. Announces New Post-Hoc Analysis of Pooled Results on the Safety and Efficacy of A Single Dose of Relistor Injection Dec 23
Insider recently bought €1.3m worth of stock Dec 02
Third quarter 2021 earnings released: EPS US$0.52 (vs US$0.20 in 3Q 2020) Nov 03
Forecast to breakeven in 2022 Oct 26
Insufficient new directors Oct 26
Forecast to breakeven in 2022 Sep 23
Independent Director recently bought €211k worth of stock Aug 07
Bausch Health Companies Inc. Revises Earnings Guidance for the Year 2021 Aug 05
Second quarter 2021 earnings released: US$1.66 loss per share (vs US$0.92 loss in 2Q 2020) Aug 04
Abu Dhabi Developmental Holding Company PJSC completed the acquisition of Amoun Pharmaceutical Company S.A.E. from Bausch Health Companies Inc. (NYSE:BHC) and others. Aug 04
Bausch + Lomb Expands Parameters for Bausch + Lomb Ultra® Multifocal for Astigmatism Contact Lenses Jun 24
Independent Director David Hale has left the company Jun 22
CFO & Executive VP recently sold €445k worth of stock Jun 16
Bausch Health and Clearside Biomedical Announce U.S. FDA Filing Acceptance for XIPERE (Triamcinolone Acetonide Suprachoroidal Injectable Suspension) Jun 03 Hissedar Getirileri BVF DE Pharmaceuticals DE Pazar 7D 0% 1.7% 0.3% 1Y 10.3% -16.3% 6.9%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: BVF geçen yıl % -16.3 oranında getiri sağlayan German Pharmaceuticals sektörünü aştı.
Getiri vs Piyasa: BVF geçen yıl % 6.9 oranında getiri sağlayan German Piyasasını aştı.
Fiyat Oynaklığı Is BVF's price volatile compared to industry and market? BVF volatility BVF Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
İstikrarlı Hisse Senedi Fiyatı: BVF hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.
Zaman İçindeki Volatilite: BVF 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri .
Şirket Hakkında Bausch Health Companies Inc. Amerika Birleşik Devletleri'nde ve uluslararası alanda çeşitlendirilmiş bir özel ilaç ve tıbbi cihaz şirketi olarak faaliyet göstermektedir. Başta gastroenteroloji, hepatoloji, nöroloji, dermatoloji, uluslararası ilaçlar, reçetesiz (OTC) ürünler, estetik tıbbi cihazlar ve göz sağlığı alanlarında bir dizi ürün geliştirmekte, üretmekte ve pazarlamaktadır. Şirket beş segmentte faaliyet göstermektedir: Salix, International, Solta Medical, Diversified ve Bausch + Lomb.
Daha fazla göster Bausch Health Companies Inc. Temel Bilgiler Özeti Bausch Health Companies'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? BVF temel i̇stati̇sti̇kler Piyasa değeri €2.86b Kazançlar(TTM ) -€171.82m Gelir(TTM ) €9.15b
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) BVF gelir tablosu (TTM ) Gelir US$9.47b Gelir Maliyeti US$2.76b Brüt Kâr US$6.71b Diğer Giderler US$6.89b Kazançlar -US$178.00m
Son Raporlanan Kazançlar
Sep 30, 2024
Hisse başına kazanç (EPS) -0.48 Brüt Marj 70.87% Net Kâr Marjı -1.88% Borç/Özkaynak Oranı -8,887.2%
BVF uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görün
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2025/01/01 04:09 Gün Sonu Hisse Fiyatı 2024/12/11 00:00 Kazançlar 2024/09/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları Bausch Health Companies Inc. 45 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Raghuram Selvaraju Aegis Capital Corporation Douglas Tsao Barclays Ardalan Arfaei BMO Capital Markets Equity Research
Göster 42 daha fazla analist 
